Showing 621 - 640 results of 1,123 for search '"prostate"', query time: 0.07s Refine Results
  1. 621

    In Vivo 3T Magnetic Resonance Imaging Using a Biologically Specific Contrast Agent for Prostate Cancer: A Nude Mouse Model by Christopher Brian Abraham, Prashant Jani, Roxanne Turuba, Michael Campbell, Ingeborg Zehbe, Laura Curiel

    Published 2017-01-01
    “…We characterized in vivo a functional superparamagnetic iron-oxide magnetic resonance contrast agent that shortens the T2 relaxation time in magnetic resonance imaging (MRI) of prostate cancer xenografts. The agent was developed by conjugating Molday ION™ carboxyl-6 (MIC6), with a deimmunized mouse monoclonal antibody (muJ591) targeting prostate-specific membrane antigen (PSMA). …”
    Get full text
    Article
  2. 622
  3. 623

    MR Imaging of Prostate Cancer: Diffusion Weighted Imaging and (3D) Hydrogen 1 (1H) MR Spectroscopy in Comparison with Histology by J. Yamamura, G. Salomon, R. Buchert, A. Hohenstein, J. Graessner, H. Huland, M. Graefen, G. Adam, U. Wedegaetner

    Published 2011-01-01
    “…Materials and Methods: 50 patients with suspicion of prostate cancer underwent a MRI examination at a 1.5T scanner. …”
    Get full text
    Article
  4. 624
  5. 625
  6. 626
  7. 627

    Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees. by Kin Wah Fung, Fitsum Baye, Seo H Baik, Clement J McDonald

    Published 2024-01-01
    “…<h4>Purpose</h4>To study the effects of benign prostatic hyperplasia treatments, namely: alpha-adrenergic receptor blockers, 5-alpha-reductase inhibitors and phosphodiesterase-5 inhibitors on the risk of Parkinson's disease, Alzheimer's disease and mortality.…”
    Get full text
    Article
  8. 628

    Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain by Eva Tirado Mercier, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut, Meritxell Granell Villalón

    Published 2018-01-01
    “…**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. …”
    Get full text
    Article
  9. 629

    A Sensitive Fluorescent Immunoassay for Prostate Specific Antigen Detection Based on Signal Amplify Strategy of Horseradish Peroxidase and Silicon Dioxide Nanospheres by Lihua Li, Wenzhi Zhang, Yan Wei, Lizhen Yu, Dexiang Feng

    Published 2022-01-01
    “…A simple, sensitive, and fluorescent immunoassay for the detection of prostate-specific antigen (PSA) based on horseradish peroxidase and silicon dioxide nanospheres as a signal amplification strategy has been described. …”
    Get full text
    Article
  10. 630
  11. 631

    Stomach Metastasis in a Patient with Prostate Cancer 4 Years after the Initial Diagnosis: A Case Report and a Literature Review by Ahmet Bilici, Mustafa Dikilitas, Ozlem Ton Eryilmaz, Bekir Selim Bagli, Fatih Selcukbiricik

    Published 2012-01-01
    “…Prostate cancer commonly metastasizes bones and lymph nodes, but it very rarely spreads to the gastrointestinal tract. …”
    Get full text
    Article
  12. 632

    A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer by Noriyuki Okonogi, MD, PhD, Hiroshi Tsuji, MD, PhD, Kana Kobayashi, MD, PhD, Mio Nakajima, MD, PhD, Shuri Aoki, MD, PhD, Takanobu Utsumi, MD, PhD, Hiroyoshi Suzuki, MD, PhD, Koichiro Akakura, MD, PhD, Tomohiko Ichikawa, MD, PhD, Hitoshi Ishikawa, MD, PhD

    Published 2025-03-01
    “…Purpose: We report herein the 3-year results of a phase I/II prospective study of 4-fraction course of carbon-ion radiation therapy (CIRT) in patients with localized prostate cancer. Methods and Materials: The present was a single-institution, phase I/II prospective study including patients with low- or intermediate-risk prostate cancer, as defined by the National Comprehensive Cancer Network criteria. …”
    Get full text
    Article
  13. 633

    Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa by Ajay Aggarwal, Janet Seeley, Virginia Bond, Kennedy Lishimpi, John Kachimba, Musonda Simwinga, Andrew Sentoogo Ssemata, Susan Msadabwe, Dorothy Chilambe Lombe, Monde Mwamba, Richard Muhumuza, Victor Mapulanga

    Published 2024-07-01
    “…National priority research areas for prostate cancer in Zambia were identified as prostate cancer awareness; building affordable high-quality diagnostic capacity; affordability of specialist cancer treatments; supporting better access to medicines; delivery and coordination of services across the pathway and staff training.Conclusion The suggested seven priority areas allow for the development of the prostate cancer control programme to be conducted in a holistic manner. …”
    Get full text
    Article
  14. 634
  15. 635

    MMP-2 and MMP-9 Activities and TIMP-1 and TIMP-2 Expression in the Prostatic Tissue of Two Ethanol-Preferring Rat Models by Beatriz Aparecida Fioruci-Fontanelli, Luiz Gustavo A. Chuffa, Leonardo O. Mendes, Patricia Fernanda F. Pinheiro, Flávia Karina Delella, Cilmery S. Kurokawa, Sérgio Luis Felisbino, Francisco Eduardo Martinez

    Published 2015-01-01
    “…These important findings demonstrate that chronic ethanol intake impairs the physiological balance of the prostate extracellular matrix turnover, through downregulation of MMPs, which may contribute to the development of prostatic diseases. …”
    Get full text
    Article
  16. 636
  17. 637
  18. 638

    Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation by Bradley A. Wall, Daniel A. Galvão, Naeem Fatehee, Dennis R. Taaffe, Nigel Spry, David Joseph, Robert U. Newton

    Published 2015-01-01
    “…One hundred and seven men (42–89 years) with prostate cancer undergoing androgen deprivation therapy completed a maximal graded objective exercise test to determine maximal oxygen uptake, assessments for resting metabolic rate, body composition, blood pressure and arterial stiffness, and blood biomarker analysis. …”
    Get full text
    Article
  19. 639
  20. 640